Red Blood Cell Transfusion Safety: Probabilistic Risk Assessment and Cost/ Benefits of Risk Reduction Strategies

Annals of Operations Research

Volumn 221, Issue 1, 2014, Pages 377-406

  Slonim, Anthony D ^a   Bish, Ebru K ^b   Xie, Ryan S ^b  

^a CARILION CLINIC   (United States)

^b Virginia Polytechnic Institute and State University   (United States)

Author keywords

Patient safety; Probabilistic risk assessment; Risk; Transfusion

Indexed keywords

EID: 85027927949     PISSN: 02545330     EISSN: 15729338     Source Type: Journal    
DOI: 10.1007/s10479-011-0925-0     Document Type: Article

References (49)

1. Alter, H. J., & Bradley, D. W. (1995). Non-A, non-B hepatitis unrelated to hepatitis C virus (non-ABC). Seminars in Liver Disease, 15, 110–120.
2. Alter, H. J., & Seeff, L. B. (2000). Recovery, persistence, and sequelae in HCV infection: A perspective on long-term outcome. Seminars in Liver Disease, 20, 17–35.
3. Bierbaum, B. E., Callaghan, J. J., & Galante, J. O. (1999). An analysis of blood management in patients having a total hip or knee arthroplasty. Journal of Bone and Joint Surgery. American Volume, 81A, 2–10.
4. Biggerstaff, B. J., & Petersen, L. R. (2003). Estimated risk of transmission of the West Nile virus through blood transfusion in the US. Transfusion, 43, 1007–1017.
5. Brower, W. A., Nainan, O. V., & Han, X. (2000). Duration of viremia in hepatitis A virus infection. The Journal of Infectious Diseases, 182, 12–17.
6. Burgmeier, J. (2002). Failure mode and effect analysis: An application in reducing risk in blood transfusion. Journal of Quality Improvement, 28, 331–339.
7. Busch, M. P. (2001). Insights into the epidemiology, natural history, and pathogenesis of hepatitis C infection from studies of infected donors and blood-product recipients. Transfusion Clinique Et Biologique, 8, 200–206.
8. Chen, B., Avrunin, G. S., Clarke, L. A., & Osterweil, L. J. (2006). Automatic fault tree derivation from little-JIL process definitions. In Q. Wang, D. Pfahl, D. Raffo, & P. Wernick (Eds.), Lecture notes in computer science: Vol.3966. Software process change (pp. 150–158). Berlin: Springer.
9. Davies, A., Staves, J., Kay, J., Casbard, A., & Murphy, M. F. (2006). End-to-end electronic control of the hospital transfusion process to increase the safety of blood transfusion: Strengths and weaknesses. Transfusion, 46, 352–364.
10. Despotis, G., Eby, C., & Lublin, D. M. (2008). A review of tansfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion, 48, 1S–30S.
11. Dodd, R. Y. (1994). Adverse Consequences of blood transfusion: Quantitative risk estimates. In S. T. Nance (Ed.), Blood supply: Risks perceptions, and prospects for the future (pp. 1–24). Bethesda: American Association of Blood Banks.
12. Dodd, R. Y., Notari, E. P., & Stramer, S. L. (2002). Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 42, 975–979.
13. Dzik, W. H. (2005). Technology for enhanced transfusion safety. American Society of Hematology (pp. 476–482).
14. Dzik, W. H., & Cooley, E. (2003). Lecture 2002: Transfusion safety in the hospital. Transfusion, 1190–1198.
15. Glynn, S. A., Kleinman, S., & Wright, D. J. (2002). International application of the incidence rate/window period model. Transfusion, 42, 966–972.
16. Goodnough, L. T. (2003). Risk of blood transfusion. Critical Care Medicine, 31(12 (Suppl.)), 680–686.
17. Goodnough, L. T., Shander, A., & Brecher, M. E. (2003). Transfusion medicine: Looking to the future. Lancet, 361, 161–169.
18. Greenwalt, T. J. (1997). A short history of transfusion medicine. Transfusion, 37, 550–563.
19. Guerrero, I. C., Weniger, B. C., & Schultz, M. G. (1983). Transfusion malaria in the United States, 1972–1981. Annals of Internal Medicine, 99, 221–226.
20. Haimes, Y. Y. (1998). Risk modeling, assessment, and management. New York: Wiley.
21. Jackson, B. R., Busch, M. P., Stramer, S. L., & AuBuchon, J. P. (2003). The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion, 43, 721–729.
22. Klein, H. G., Spahn, D. R., & Carson, J. L. (2007). Red blood cell transfusion in clinical practice. Lancet, 370, 415–426.
23. Kleinman, S. H., & Busch, M. (2001). Hepatitis B virus amplified and back in the blood safety spotlight. Transfusion, 41, 1081–1085.
24. Kleinman, S., Busch, M. P., & Korelitz, J. J. (1997). The incidence/window period model and its use to assess the risk of transfusion-transmitted HIV and HCV infection. Transfusion Medicine Reviews, 11, 155–172.
25. Kleinman, S., Chan, P., & Robillard, P. (2003a). Risks associated with transfusion of cellular blood components in Canada. Transfusion Medicine Reviews, 17(2), 120–162.
26. Kleinman, S. H., Kuhns, M. C., & Todd, D. S. (2003b). Frequency of HBV DNA detection in US blood donors positive for anti-HBC: Implications for transfusion transmission and donor screening. Transfusion, 43(6), 696–704.
27. Kumamoto, H., & Henley, E. J. (2000). Probabilistic risk assessment and management for engineers and scientists (2nd ed.). New York: Wiley-IEEE Press.
28. Laupacis, A., Brown, J., & Costello, B. (2001). Prevention of posttransfusion CMV in the era of universal leukoreduction: A consensus statement. Transfusion, 41, 560–569.
29. Leiby, D. A. (2001). Parasites and other emergent infectious agents. In S. Stramer (Ed.), Blood safety in the new millenium (pp. 55–78). Bethesda: American Association of Blood Banks.
30. Linden, J. V., Wagner, K., & Voytovich, A. E. (2000). Transfusion errors in New York State: An analysis of 10 years’ experience. Transfusion, 40, 1207–1213.
31. Lyons, M., Adams, S., Woloshynowych, M., & Vincent, C. (2004). Human reliability analysis in healthcare: A review of techniques. The International Journal of Risk and Safety in Medicine16, 223–237.
32. Mayer, K. (1982). A Different view of transfusion safety—Type and screen, transfusion of Coombs incompatible cells, and fatal transfusion induced graft versus host disease. In H. F. Polesky & R. H. Walker (Eds.), Safety in transfusion practices. Skokie: College of American Pathologists.
33. Mazzei, C. A., Popovsky, M. A., & Kopko, P. M. (2002). Noninfectious complications of blood transfusion. In M. E. Brecher (Ed.), AABB technical manual (14th ed.) (pp. 586–587). Bethesda: American Association of Blood Banks.
34. Mungai, M., Tegtmeier, G., & Chamberland, M. (2001). Transfusion-transmitted malaria in the United States from 1963 through 1999. The New England Journal of Medicine, 344, 1973–1978.
35. Pineda, A. A., Vamvakas, E. C., & Gorden, L. D. (1999). Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion, 39, 1097–1103.
36. Popovsky, M. A., & Moore, S. B. (1985). Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion, 25, 573–577.
37. Popovsky, M. A., & Taswell, H. F. (1985). Circulatory overload: An underdiagnosed consequence of transfusion. Transfusion, 25, 469.
38. Preiksaitis, J. K. (2000). The cytomegalovirus “safe” blood product: Is leukoreduction equivalent to antibody screening? Transfusion Medicine Reviews, 14, 112–136.
39. Rausand, M., & Høyland, A. (2004). Wiley series in probability and statistics. System reliability theory: Models, statistical methods, and applications (2nd ed.). Hoboken: Wiley-Interscience.
40. Ross, S. M. (2007). Introduction to probability models. Amsterdam: Academic Press.
41. Saxena, S., Ramer, L., & Shulman, I. A. (2004). A comprehensive assessment program to improve blood-administering practices Using the FOCUS–PDCA model. Transfusion, 44, 1350–1356.
42. Schaefer, A. J., Bailey, M. D., Shechter, S. M., & Roberts, M. S. (2004). Modeling medical treatment using Markov decision processes. In M. L. Brandeau, F. Sainfort, & W. P. Pierskalla (Eds.), Kluwer’s International SeriesOperations research and health care (pp. 593–612). Berlin: Springer.
43. Schreiber, G. B., Busch, M. P., & Kleinman, S. H. (1996). The risk of transfusion-transmitted viral infection. The New England Journal of Medicine, 334, 1685–1690.
44. Stockwell, D. C., & Slonim, A. D. (2006). Quality and safety in the intensive care unit. Journal of Intensive Care Medicine, 21(4), 199–210.
45. Stramer, S. L. (2007). Current risks of transfusion-transmitted agents: A review. Archives of Pathology & Laboratory Medicine, 131, 702–707.
46. Stramer, S. L., Dodd, R. Y., & Leiby, D. A. (2007). Blood donor screening for Chagas disease—United States, 2006–2007. Morbidity and Mortality Weekly Report, 56, 141–143.
47. Trammell, S. R., & Wright, R. D. (1999). Integrating risk assessment into management systems. In Electronics manufacturing technology symposium twenty-fourth IEEE/CPMT (pp. 156–159).
48. Turner, C. L., Casbard, A. C., & Murphy, M. F. (2003). Barcode technology: Its role in increasing the safety of blood transfusion. Transfusion, 43, 1200–1209.
49. Williamson, L. M., & Warwick, R. M. (1995). Transfusion-associated graft-versus-host disease and its prevention. The Blood Review, 9, 251–261.